e-learning
resources
Monograph
2022
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Treating sarcoidosis and potential new drugs
Canay Caliskan, Antje Prasse
Source:
Eur Respir Monogr 2022; 96: 328-336
Journal Issue:
Sarcoidosis
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Canay Caliskan, Antje Prasse. Treating sarcoidosis and potential new drugs. Eur Respir Monogr 2022; 96: 328-336
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
Atypical mycobacteriosis : new drugs, new strategies
Source: Annual Congress 2004 - PG11 - Multiresistant tuberculosis and atypical mycobacterial disease
Year: 2004
Fibrocytes: potential new therapeutic targets for pulmonary hypertension?
Source: Eur Respir J 2010; 36: 1232-1235
Year: 2010
Therapeutic options for sarcoidosis: old and new
Source: Annual Congress 2005 - PG15 - Therapeutic options for interstitial lung diseases in 2005
Year: 2005
An evidence-based and step-wise approach to treat pulmonary sarcoidosis with old and new drugs
Source: International Congress 2019 – State of the art session: Interstitial lung diseases
Year: 2019
The challenges of severe pneumonia: new pathogens, new drugs and new formulations
Source: Virtual Congress 2021 – Respiratory infections
Year: 2021
Late Breaking Abstract - Anti-inflammatory activity of novel transtilbene sulfonamide analogues as potential novel therapeutic agents for inflammatory lung disease
Source: International Congress 2019 – COPD treatment: cardiovascular, oxygen and vaccination studies
Year: 2019
Combining corticosteroids and NK1R antagonists: A new drugs combination to treat allergic diseases
Source: Annual Congress 2012 - The best of pharmacology treatment for asthma and COPD
Year: 2012
Antibiotics as immunomodulators: a potential pharmacologic approach for ARDS treatment
Source: Eur Respir Rev, 30 (162) 210093; 10.1183/16000617.0093-2021
Year: 2021
Clinical implications and opportunities for new drug therapies
Source: Annual Congress 2008 - Deadly networks: disease-causing protein and DNA modifications
Year: 2008
Late Breaking Abstract - The outcome of COVID-19 in interstitial lung disease patients treated with anti-inflammatory drugs and antiviral drugs
Source: Virtual Congress 2021 – Prognostic markers of disease progression in non-idiopathic pulmonary fibrosis interstitial lung diseases
Year: 2021
New drugs for severe asthma – what should we target and how?
Source: Research Seminar 2014 - Human translational medicine: a key bridge for the development of new drugs for severe asthma, COPD and ILD
Year: 2014
Potential of regulatory T-cell-based therapies in the management of severe COVID-19
Source: Eur Respir J, 56 (3) 2002182; 10.1183/13993003.02182-2020
Year: 2020
COPD mechanisms: novel aspects and implications for new therapies
Source: ERS Live 2007
Year: 2007
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept